2020
Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation
Dawwas GK, Brensinger CM, Vajravelu RK, Wu Q, Kelly CR, Laine L, Wu GD, Lewis JD. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clinical Gastroenterology And Hepatology 2020, 20: 806-816.e6. PMID: 33307184, PMCID: PMC8184854, DOI: 10.1016/j.cgh.2020.12.004.Peer-Reviewed Original ResearchMeSH KeywordsClostridioides difficileClostridium InfectionsFecal Microbiota TransplantationHumansRecurrenceReproducibility of ResultsRetrospective StudiesConceptsFecal microbiota transplantationIrritable bowel syndromeImmune-mediated diseasesBowel syndromeMyocardial infarctionMicrobiota transplantationRecurrent Clostridioides difficile infectionRecurrent Clostridioides difficileRetrospective cohort studyImmune-mediated conditionsInflammatory bowel diseaseInflammatory bowel syndromeCommercial claims databaseLong-term outcomesClostridioides difficile infectionCohort studyBowel diseaseMicrobiota disturbanceRheumatoid arthritisClaims databaseDifficile infectionHigh riskHigh incidenceGut microbiotaSignificant associationFecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020, 160: 183-192.e3. PMID: 33011173, PMCID: PMC8034505, DOI: 10.1053/j.gastro.2020.09.038.Peer-Reviewed Original ResearchConceptsClostridioides difficile infectionMicrobiota transplantationSafety profileNational registryProspective real-world studyFull safety profileProspective safety dataBaseline patient characteristicsInflammatory bowel diseaseIrritable bowel syndromeFecal microbiota transplantationLong-term safety outcomesGood safety profileReal-world studyAbdominal painBowel syndromePatient characteristicsReal-world practiceBowel diseaseCDI recurrenceDifficile infectionSafety dataSafety outcomesEffectiveness outcomesSevere symptomsMonitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment
Kelly CR, Laine LA, Wu GD. Monitoring Fecal Microbiota Transplantation Practice in a Rapidly Evolving Health and Regulatory Environment. Gastroenterology 2020, 159: 2004-2006. PMID: 32841646, PMCID: PMC7443160, DOI: 10.1053/j.gastro.2020.08.039.Commentaries, Editorials and Letters
2017
The AGA’s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics
Kelly CR, Kim AM, Laine L, Wu GD. The AGA’s Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics. Gastroenterology 2017, 152: 681-684. PMID: 28143773, DOI: 10.1053/j.gastro.2017.01.028.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsFecal Microbiota TransplantationFecesGastrointestinal MicrobiomeHumansPatient SafetyRegistriesRisk AssessmentRisk FactorsTreatment OutcomeUnited States